{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T04:01:30Z","timestamp":1782360090860,"version":"3.54.5"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Department of Health & Human Services | U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["None"],"award-info":[{"award-number":["None"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Direct oral anticoagulants (DOACs) targeting activated factor Xa (FXa) are used to prevent or treat thromboembolic disorders. DOACs reversibly bind to FXa and inhibit its enzymatic activity. However, DOAC treatment carries the risk of anticoagulant-associated bleeding. Currently, only one specific agent, andexanet alfa, is approved to reverse the anticoagulant effects of FXa-targeting DOACs (FXaDOACs) and control life-threatening bleeding. However, because of its mechanism of action, andexanet alfa requires a cumbersome dosing schedule, and its use is associated with the risk of thrombosis. Here, we present the computational design, engineering, and evaluation of FXa-variants that exhibit anticoagulation reversal activity in the presence of FXaDOACs. Our designs demonstrate low DOAC binding affinity, retain FXa-enzymatic activity and reduce the DOAC-associated bleeding by restoring hemostasis in mice treated with apixaban. Importantly, the FXaDOACs reversal agents we designed, unlike andexanet alfa, do not inhibit TFPI, and consequently, may have a safer thrombogenic profile.<\/jats:p>","DOI":"10.1038\/s41467-024-48278-1","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T15:02:24Z","timestamp":1715266944000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Engineering and evaluation of FXa bypassing agents that restore hemostasis following Apixaban associated bleeding"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7000-9057","authenticated-orcid":false,"given":"Wojciech","family":"Jankowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5796-2155","authenticated-orcid":false,"given":"Stepan S.","family":"Surov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8307-4704","authenticated-orcid":false,"given":"Nancy E.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3443-693X","authenticated-orcid":false,"given":"Atul","family":"Rawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Battistel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1991-5174","authenticated-orcid":false,"given":"Daron","family":"Freedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail V.","family":"Ovanesov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8202-5188","authenticated-orcid":false,"given":"Zuben E.","family":"Sauna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,9]]},"reference":[{"key":"48278_CR1","doi-asserted-by":"publisher","unstructured":"Lim, G. B. Milestone 2: Warfarin: from rat poison to clinical use. Nat Rev Cardiolhttps:\/\/doi.org\/10.1038\/nrcardio.2017.172 (2017).","DOI":"10.1038\/nrcardio.2017.172"},{"key":"48278_CR2","doi-asserted-by":"publisher","first-page":"e017559","DOI":"10.1161\/JAHA.120.017559","volume":"9","author":"A Chen","year":"2020","unstructured":"Chen, A., Stecker, E. & B, A. W. Direct oral anticoagulant use: a practical guide to common clinical challenges. J. Am. Heart Assoc. 9, e017559 (2020).","journal-title":"J. Am. Heart Assoc."},{"key":"48278_CR3","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","volume":"124","author":"N van Es","year":"2014","unstructured":"van Es, N., Coppens, M., Schulman, S., Middeldorp, S. & Buller, H. R. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 124, 1968\u20131975 (2014).","journal-title":"Blood"},{"key":"48278_CR4","doi-asserted-by":"publisher","DOI":"10.1177\/1076029619847524","volume":"25","author":"F Siddiqui","year":"2019","unstructured":"Siddiqui, F. et al. Factor Xa inhibitory profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban does not fully reflect their biologic spectrum. Clin. Appl Thromb. Hemost. 25, 1076029619847524 (2019).","journal-title":"Clin. Appl Thromb. Hemost."},{"key":"48278_CR5","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1182\/blood-2018-04-791541","volume":"132","author":"JM Connors","year":"2018","unstructured":"Connors, J. M. Testing and monitoring direct oral anticoagulants. Blood 132, 2009\u20132015 (2018).","journal-title":"Blood"},{"key":"48278_CR6","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff, C. T. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383, 955\u2013962 (2014).","journal-title":"Lancet"},{"key":"48278_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/clc.22373","volume":"38","author":"S Tamayo","year":"2015","unstructured":"Tamayo, S. et al. Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban. Clin. Cardiol. 38, 63\u201368 (2015).","journal-title":"Clin. Cardiol."},{"key":"48278_CR8","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1182\/hematology.2019000072","volume":"2019","author":"DM Siegal","year":"2019","unstructured":"Siegal, D. M. What we have learned about direct oral anticoagulant reversal. Hematol. Am. Soc. Hematol. Educ. Program 2019, 198\u2013203 (2019).","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"48278_CR9","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1001\/jama.2021.13844","volume":"326","author":"DS Budnitz","year":"2021","unstructured":"Budnitz, D. S. et al. US emergency department visits attributed to medication harms, 2017-2019. JAMA 326, 1299\u20131309 (2021).","journal-title":"JAMA"},{"key":"48278_CR10","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nm.3102","volume":"19","author":"G Lu","year":"2013","unstructured":"Lu, G. et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat. Med 19, 446\u2013451 (2013).","journal-title":"Nat. Med"},{"key":"48278_CR11","first-page":"530","volume":"44","author":"JH Momin","year":"2019","unstructured":"Momin, J. H., Candidate, P. & Hughes, G. J. Andexanet Alfa (Andexxa((R))) for the reversal of direct oral anticoagulants. P T 44, 530\u2013549 (2019).","journal-title":"P T"},{"key":"48278_CR12","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1016\/j.jacc.2021.04.061","volume":"77","author":"A Gomez-Outes","year":"2021","unstructured":"Gomez-Outes, A. et al. Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants. J. Am. Coll. Cardiol. 77, 2987\u20133001 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"48278_CR13","doi-asserted-by":"publisher","first-page":"e2240145","DOI":"10.1001\/jamanetworkopen.2022.40145","volume":"5","author":"R Chaudhary","year":"2022","unstructured":"Chaudhary, R. et al. Evaluation of direct oral anticoagulant reversal agents in intracranial hemorrhage: a systematic review and meta-analysis. JAMA Netw. Open 5, e2240145 (2022).","journal-title":"JAMA Netw. Open"},{"key":"48278_CR14","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","volume":"380","author":"SJ Connolly","year":"2019","unstructured":"Connolly, S. J. et al. Full study report of Andexanet Alfa for bleeding associated with factor Xa inhibitors. N. Engl. J. Med 380, 1326\u20131335 (2019).","journal-title":"N. Engl. J. Med"},{"key":"48278_CR15","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1055\/s-0040-1709134","volume":"46","author":"M Schreuder","year":"2020","unstructured":"Schreuder, M., Reitsma, P. H. & Bos, M. H. A. Reversal agents for the direct factor Xa inhibitors: biochemical mechanisms of current and newly emerging therapies. Semin Thromb. Hemost. 46, 986\u2013998 (2020).","journal-title":"Semin Thromb. Hemost."},{"key":"48278_CR16","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/nm.4149","volume":"22","author":"NK Thalji","year":"2016","unstructured":"Thalji, N. K. et al. A rapid pro-hemostatic approach to overcome direct oral anticoagulants. Nat. Med 22, 924\u2013932 (2016).","journal-title":"Nat. Med"},{"key":"48278_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00647-9","volume":"8","author":"D Verhoef","year":"2017","unstructured":"Verhoef, D. et al. Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors. Nat. Commun. 8, 528 (2017).","journal-title":"Nat. Commun."},{"key":"48278_CR18","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/nature12443","volume":"501","author":"CE Tinberg","year":"2013","unstructured":"Tinberg, C. E. et al. Computational design of ligand-binding proteins with high affinity and selectivity. Nature 501, 212\u2013216 (2013).","journal-title":"Nature"},{"key":"48278_CR19","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41592-020-0848-2","volume":"17","author":"JK Leman","year":"2020","unstructured":"Leman, J. K. et al. Macromolecular modeling and design in Rosetta: recent methods and frameworks. Nat. Methods 17, 665\u2013680 (2020).","journal-title":"Nat. Methods"},{"key":"48278_CR20","doi-asserted-by":"publisher","first-page":"W210","DOI":"10.1093\/nar\/gkac387","volume":"50","author":"L Holm","year":"2022","unstructured":"Holm, L. Dali server: structural unification of protein families. Nucleic Acids Res 50, W210\u2013W215 (2022).","journal-title":"Nucleic Acids Res"},{"key":"48278_CR21","doi-asserted-by":"publisher","first-page":"e026863","DOI":"10.1161\/JAHA.122.026863","volume":"12","author":"TG Simon","year":"2023","unstructured":"Simon, T. G., Schneeweiss, S., Singer, D. E., Sreedhara, S. K. & Lin, K. J. Prescribing trends of oral anticoagulants in US patients with Cirrhosis and Nonvalvular Atrial Fibrillation. J. Am. Heart Assoc. 12, e026863 (2023).","journal-title":"J. Am. Heart Assoc."},{"key":"48278_CR22","doi-asserted-by":"publisher","unstructured":"Verdin, P. Top product forecasts for 2024. Nature Reviews Drug Discovery 23, https:\/\/doi.org\/10.1038\/d41573-023-00198-3 (2023).","DOI":"10.1038\/d41573-023-00198-3"},{"key":"48278_CR23","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1161\/CIRCRESAHA.112.276741","volume":"111","author":"CH Yeh","year":"2012","unstructured":"Yeh, C. H., Fredenburgh, J. C. & Weitz, J. I. Oral direct factor Xa inhibitors. Circ. Res 111, 1069\u20131078 (2012).","journal-title":"Circ. Res"},{"key":"48278_CR24","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/j.1538-7836.2007.02473.x","volume":"5","author":"J Ansell","year":"2007","unstructured":"Ansell, J. Factor Xa or thrombin: is factor Xa a better target? J. Thromb. Haemost. 5, 60\u201364 (2007).","journal-title":"J. Thromb. Haemost."},{"key":"48278_CR25","doi-asserted-by":"publisher","first-page":"5339","DOI":"10.1021\/jm070245n","volume":"50","author":"DJ Pinto","year":"2007","unstructured":"Pinto, D. J. et al. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J. Med Chem. 50, 5339\u20135356 (2007).","journal-title":"J. Med Chem."},{"key":"48278_CR26","doi-asserted-by":"crossref","unstructured":"Roehrig, S. et al. Discovery of the novel antithrombotic agent 5-chloro-N-((5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-ylmethyl)thiophene- 2-carboxamide (BAY 59\u22127939): an oral, direct factor Xa inhibitor. J. Med. Chem. 48, 5900\u20135908 (2005).","DOI":"10.1021\/jm050101d"},{"key":"48278_CR27","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1055\/a-1450-8178","volume":"121","author":"J Douxfils","year":"2021","unstructured":"Douxfils, J. et al. 2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. Thromb. Haemost. 121, 1008\u20131020 (2021).","journal-title":"Thromb. Haemost."},{"key":"48278_CR28","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1182\/bloodadvances.2020001699","volume":"4","author":"A von Drygalski","year":"2020","unstructured":"von Drygalski, A. et al. An engineered factor Va prevents bleeding induced by direct-acting oral anticoagulants by different mechanisms. Blood Adv. 4, 3716\u20133727 (2020).","journal-title":"Blood Adv."},{"key":"48278_CR29","doi-asserted-by":"publisher","first-page":"e483","DOI":"10.3324\/haematol.2017.174037","volume":"102","author":"A Ersayin","year":"2017","unstructured":"Ersayin, A. et al. Catalytically inactive Gla-domainless factor Xa binds to TFPI and restores ex vivo coagulation in hemophilia plasma. Haematologica 102, e483\u2013e485 (2017).","journal-title":"Haematologica"},{"key":"48278_CR30","first-page":"312","volume":"117","author":"E Lindhoff-Last","year":"2020","unstructured":"Lindhoff-Last, E. et al. Severe hemorrhage associated with oral anticoagulants. Dtsch Arztebl Int 117, 312\u2013319 (2020).","journal-title":"Dtsch Arztebl Int"},{"key":"48278_CR31","doi-asserted-by":"publisher","first-page":"3981","DOI":"10.1038\/s41596-021-00568-4","volume":"16","author":"LA Parunov","year":"2021","unstructured":"Parunov, L. A. et al. Thrombin generation test based on a 96-channel pipettor for evaluation of FXIa procoagulant activity in pharmaceuticals. Nat. Protoc. 16, 3981\u20134003 (2021).","journal-title":"Nat. Protoc."},{"key":"48278_CR32","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","volume":"22","author":"S Reagan-Shaw","year":"2008","unstructured":"Reagan-Shaw, S., Nihal, M. & Ahmad, N. Dose translation from animal to human studies revisited. FASEB J. 22, 659\u2013661 (2008).","journal-title":"FASEB J."},{"key":"48278_CR33","unstructured":"FDA\/CDER estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Guidance for Industry (2005)."},{"key":"48278_CR34","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.tibtech.2018.05.008","volume":"36","author":"ZE Sauna","year":"2018","unstructured":"Sauna, Z. E., Lagasse, D., Pedras-Vasconcelos, J., Golding, B. & Rosenberg, A. S. Evaluating and mitigating the immunogenicity of therapeutic proteins. Trends Biotechnol. 36, 1068\u20131084 (2018).","journal-title":"Trends Biotechnol."},{"key":"48278_CR35","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/jcc.20291","volume":"26","author":"D Van Der Spoel","year":"2005","unstructured":"Van Der Spoel, D. et al. GROMACS: fast, flexible, and free. J. Comput Chem. 26, 1701\u20131718 (2005).","journal-title":"J. Comput Chem."},{"key":"48278_CR36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","volume":"14","author":"W Humphrey","year":"1996","unstructured":"Humphrey, W., Dalke, A. & Schulten, K. VMD: visual molecular dynamics. J. Mol. Graph 14, 33\u201338 (1996). 27-38.","journal-title":"J. Mol. Graph"},{"key":"48278_CR37","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.3390\/biom12121764","volume":"12","author":"S Rosignoli","year":"2022","unstructured":"Rosignoli, S. & Paiardini, A. Boosting the full potential of PyMOL with structural biology plugins. Biomolecules 12, 1764 (2022).","journal-title":"Biomolecules"},{"key":"48278_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-10-168","volume":"10","author":"V Le Guilloux","year":"2009","unstructured":"Le Guilloux, V., Schmidtke, P. & Tuffery, P. Fpocket: an open source platform for ligand pocket detection. BMC Bioinforma. 10, 168 (2009).","journal-title":"BMC Bioinforma."},{"key":"48278_CR39","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/laban0511-155","volume":"40","author":"T Yardeni","year":"2011","unstructured":"Yardeni, T., Eckhaus, M., Morris, H. D., Huizing, M. & Hoogstraten-Miller, S. Retro-orbital injections in mice. Lab Anim. (NY) 40, 155\u2013160 (2011).","journal-title":"Lab Anim. (NY)"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-48278-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-48278-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-48278-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T15:02:56Z","timestamp":1715266976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-48278-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,9]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["48278"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-48278-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,9]]},"assertion":[{"value":"25 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3912"}}